IngredientsTheacrine (1,3,7,9-tetramethyluric acid) is a naturally occurring purine alkaloid, present in Camellia assamica variety kucha tea. It is a wild tea plant species, formerly named Camellia assamica var. kucha, and its full systematic name is 1,3,7,9-tetramethyl-1H-purine-2,6,8(3H,7H,9H)-trione, with the chemical formula C9H12N4O3 and molecular weight 224.22. Other names include Temurin, Temorine, Tetramethyluric acid, and Tetramethyl uric acid, with an IUPAC name of 1,3,7,9-tetramethylpurine-2,6,8-trione. Its unique chemical registry number is 2309-49-1.
Theacrine is a caffeine-like xanthine alkaloid with an additional methyl group at N9 and a keto group at C8. It is structurally related to caffeine and possesses stimulant, analgesic, and anti-inflammatory effects. 1,3,7,9-tetramethyluric acid, commonly known as theacrine, was not formally studied until around 1975; however, it has been known since about 1937, when it was detected in dry, decaffeinated Camellia sinensis tea leaves.
Theacrine, an alkaloid purine similar to caffeine, is relatively rare and only found in a few varieties of tea (kucha tea, genus Camellia), the fruit cupuaçu, and other plants related to coffee and cacao (genera Coffea and Theobroma), such as Coffea liberica, Coffea dewevrei, Coffea abeokutae, and Theobroma grandiflorum. Theacrine is also found in stenophylla coffee.
At this time, the Camellia assamica var. kucha variety of tea is the primary source of naturally occurring theacrine and produces the chemical in higher concentrations than other known plants. The cupuaçu plant is related to cocoa and grows in the Amazon. The kucha plant is related to the tea plant and grows only in the wild woods of Yunnan, China, above an altitude of 1,000 meters, and is used to make Chinese kucha tea.
Theacrine has also been detected in Camellia sinensis var. puanensis, Ilex vomitoria, and Camellia gymnogyna. Interestingly, theacrine has not been detected at all in more traditional tea strains.
At least ten compounds have been isolated and identified from the leaves of Camellia assamica var. kucha: theacrine, caffeine, theobromine, catechin, epigallocatechin, gallocatechin, epigallocatechin 3-o-gallate, gallocatechin 3-o-gallate, 1,2,6-tri-o-gallogl-beta-D-glucose, and gallic acid.
TeaCrine® is a nature-identical, chemically equivalent bioactive version of theacrine. Commercially, theacrine is usually sold as a branded ingredient (often labeled as TeaCrine) in capsules, tablets, or powder, either by itself or combined with caffeine and other stimulants in pre-workout and energy formulas. Certain botanical materials may possess a stimulant effect, while the "naturally derived" form means the stimulant (e.g., theacrine) is in a purified form, outside its natural botanical matrix.
Two types of Chinese kucha (bitter) tea are traditionally consumed for health improvement; one is Kuding tea, and the other is Yunnan Kucha tea prepared from young leaves of Camellia assamica var. kucha Chang et Wang. Camellia assamica var. kucha is naturally grown in certain mountain areas of Yunnan, China, and is assumed to be a mutant variety of wild Pu'er tea plant (Camellia sinensis var. assamica). Yunnan Kucha tea is also called bitter Pu'er tea or Pu'er Kucha tea.
The fresh young leaves and shoots are picked by the indigenous people in local mountain areas of Yunnan to prepare an herbal tea for the treatment of common cold empirically. Two extra compounds of relative abundance were detected in Kucha tea in comparison with Pu'er tea, and their chemical structures were identified as chlorogenic acid and theacrine.
Kucha, a unique variety of Camellia sinensis with a bitter taste in both fresh leaves and made tea, was first found in Yunnan province, with most plants located in the adjoining regions between Guangxi, Guangdong, Hunan, and Jiangxi provinces in China. Kucha plants are usually semi-arbor trees with large leaves. The leaves of Kucha are remarkably characterized by their strongly bitter taste and special aroma compared to other tea cultivars. In the Kucha-growing regions, local residents popularly use its leaves as a medicine to treat wounds, inflammation, and diarrhea in daily life.
Historically, the leaves containing theacrine have been brewed into traditional teas, referred to as "kucha tea," prized for their invigorating properties. In traditional Chinese medicine, kucha tea was valued as a remedy to combat fatigue, enhance mental clarity, and promote overall vitality. It was sometimes used to ease symptoms of mild pain and inflammation, thanks to theacrine's reported analgesic properties.
It is suggested that theacrine and strictinin are two major ingredients responsible for the anti-influenza activity of Yunnan Kucha tea, which was traditionally used for the treatment of the common cold.
It is important to note that the historical record specifically addresses kucha tea as a whole botanical product. The isolation of theacrine as a discrete compound is a modern scientific development; no traditional pharmacopeia or official monograph specifically attributed theacrine itself—separate from the whole tea preparation—as the responsible constituent for these traditional uses.
Recent studies reveal that caffeine can be converted into theacrine in the rare tea plant Camellia assamica var. kucha, which involves oxidation at the C8 and methylation at the N9 positions of caffeine. The theacrine synthase CkTcS from Kucha possesses novel N9-methyltransferase activity, using 1,3,7-trimethyluric acid but not caffeine as a substrate, confirming that C8 oxidation takes place prior to N9-methylation.
Research has shown that the content of theacrine is highly negatively correlated with caffeine content (R2 > 0.9) in kucha plants.
The exact mechanism of action of theacrine is uncertain, as no binding affinities have been published. However, animal research involving selective A1 and A2A adenosine agonists found theacrine pretreatment attenuated the expected motor depression induced by adenosine agonism, indicating that theacrine is likely an adenosine antagonist. Theacrine, a methylurate class purine alkaloid, triggers diverse pharmacologic responses, including psychostimulatory activity by modulation of adenosinergic and dopaminergic pathways.
In rats, the administration of theacrine reversed the motor depression induced by adenosine receptor agonists, whereas theacrine-induced hyperlocomotion was reversed by dopamine receptor antagonists, suggesting that theacrine's psychostimulatory mechanism of action involves modulation of the adenosinergic and dopaminergic pathways.
Administration of selective dopamine D1 and D2 antagonists demonstrates that, similarly to caffeine, the behavioral effects of theacrine are in part mediated by dopamine receptors. These findings demonstrate that theacrine significantly enhances activity; an effect which is mediated by both the adenosinergic and dopaminergic systems.
Theacrine is thought to act through both the adenosine and dopamine systems to provide a mild stimulant effect, as well as a calming effect. It is structurally similar to caffeine and has been reported to have antioxidant, anti-inflammatory/analgesic, anti-depressive, locomotor, and sedative/hypnotic properties.
Theacrine upregulates the expression of SIRT3 and activates the SIRT3/FOXO3/SOD2 signaling pathway, resulting in antioxidant efficiency. In mouse studies, theacrine protected against liver damage by reducing the levels of inflammatory cytokines IL-1β, TNF-α, IL-6, and IFN-γ in the liver. It also increased the antioxidant capacity of the blood and liver of stressed mice. Theacrine increased the production of the antioxidant enzymes superoxide dismutase, catalase, and glutathione peroxidase, and reduced the activity of xanthine oxidase (an enzyme that creates reactive oxygen species).
Theacrine upregulates the expression of RNA and protein of SMAD3, p-ERK, and p-p38, and downregulates the expression of NF-ÎşB and IL-6, showing anti-inflammatory effects.
Theacrine acts as an adenosine receptor antagonist to play a role in locomotor activation and fatigue reduction. Theacrine regulates brain glucose metabolism, inhibits phosphodiesterases, and restores the levels of 5-HTP and dopamine to improve cognitive capacity.
Theacrine is shown to be stimulatory when used in higher doses; however, it can actually have a sedative effect when used in low doses such as the amount consumed through tea leaves of C. kucha. Oral administration of theacrine (10 and 30 mg/kg) could significantly prolong sleeping time in animal models. Theacrine possesses potent sedative and hypnotic properties, and its central nervous system effects occur through mediating the adenosine system.
Theacrine ameliorates lipid metabolism by activating the SIRT3/AMPK/ACC pathway and downregulating the mRNA and protein levels of fatty acid synthase, fatty acid translocase, and stearoyl-coenzyme A desaturase.
Despite its structural similarity to caffeine, theacrine does not cause side effects such as anxiety and dehydration. Theacrine is a purine alkaloid that is converted from caffeine by hydration, oxidation, and methylation, and it is thought to influence the central nervous system as a neuroactive ingredient.
An initial two-part pilot study involving 15 human subjects found that theacrine (Teacrine™) delivered at an acute dose of 200 mg promoted a significant increase in energy, a reduction in fatigue, and a trend (p = 0.07) towards improved concentration (based on a subjective questionnaire) compared to a placebo group.
Using a two-part approach in humans, the impact of theacrine (TeaCrine®) was used to examine subjective dose-response, daily changes in cognitive and psychometric parameters, and changes in gas exchange and vital signs. Part 1 was a randomized, open-label, dose-response investigation in nine healthy participants whereby three participants ingested 400 mg TC per day and six participants ingested 200 mg/day. Participants recorded subjective changes using 150-mm anchored visual analog scale (VAS) before, and 1, 4, and 6 hours after ingestion every day for 7 consecutive days.
Energy, focus, and concentration increased from baseline values in both doses with no dose-response effect. VAS responses in the 200 mg group for willingness to exercise, anxiety, motivation to train, and libido increased across the measurement period, while no such change was seen with the 400 mg dose. After consuming a single 200 mg dose, significant group Ă— time interaction effects were seen for energy, fatigue, and concentration. No changes in resting heart rate, gas exchange, systemic hemodynamics, or side effect profiles were noted.
In a double-blind, placebo-controlled study, theacrine increased energy, concentration, and mood, while reducing fatigue.
Evidence strength: Preliminary. Human studies in this area used small samples, subjective rating scales, and short durations. Results are directionally consistent but require replication in larger, rigorously powered trials.
Theacrine is a purine alkaloid found primarily in the leaves of the Camellia Kucha plant and is now included within dietary supplements. To compare the effects of a theacrine-containing dietary supplement with caffeine and placebo on energy, mood, and objective measures of cognitive performance, heart rate, and blood pressure, 10 healthy men (20.8 ± 0.7 years) and 10 healthy women (22.2 ± 1.1 years) ingested the dietary supplement TheaTrim (containing a branded form of theacrine and caffeine, 150 mg), caffeine only (150 mg), or a placebo on three different days. Subjects completed tests of cognitive performance (trail making test, digit symbol substitution test) and reaction time for up to 4 h following ingestion.
There is interest in identifying alternative supplements that improve cognitive performance without compromising subsequent sleep. One study investigated the influence of dose and timing of theacrine consumption on cognitive performance and subsequent sleep using conditions that replicate a low (100 mg) and high (400 mg) dose consumed in the morning (12 hours prior to bedtime), afternoon (8 hours prior to bedtime), and evening (4 hours prior to bedtime). The authors found no significant effect of the low or high theacrine dose on subsequent sleep, although the high dose showed small non-significant effects on sleep efficiency and wake after sleep onset at each timepoint of consumption.
Prior to the intervention, two participants withdrew; therefore, 22 healthy males (age: 25.0 ± 4.6 years) with moderate habitual caffeine intake (136.7 ± 82.5 mg/day) completed the study. No adverse events were reported during data collection.
An acute dose of 200 mg significantly increased energy and reduced fatigue when assessed using visual analogue scales, while the acute intake of 300 mg had no significant effect on arousal when assessed using visual analogue scales or an adapted Profile of Moods States.
A repeated-measure, randomized crossover study compared the effects of caffeine (125 mg), caffeine (125 mg) + Dynamine® (75 mg) + TeaCrine® (50 mg), and matched placebo across three testing sessions among 50 young male egamers. Multiple measures of cognition, self-reported mood, and biomarkers of arousal (cortisol and salivary alpha-amylase) were tested, as well as electroencephalogram power during the cognitive tasks.
Theacrine regulates brain glucose metabolism, inhibits phosphodiesterases, and restores the levels of 5-HTP and dopamine to improve cognitive capacity — though this mechanistic understanding currently derives from animal and cell-based studies, not human clinical trials.
Evidence strength: Preliminary to modest. Most studies tested theacrine in combination with caffeine and other compounds, making it difficult to isolate theacrine's independent effect on cognition. Sample sizes are small. Dose-response patterns have been inconsistent across studies.
Theacrine (1,3,7,9-tetramethyluric acid) is a pure alkaloid with a similar structure to caffeine and acts comparably as an adenosine receptor antagonist. Early studies have shown non-habituating effects, including increases in energy and focus in response to TeaCrine®. One study investigated the effects of TeaCrine® and caffeine on cognitive performance and time-to-exhaustion during a simulated soccer game in high-level male and female athletes.
Theacrine has been evaluated as a means to augment, and thus potentially reduce the dose of, caffeine in clinical substantiation studies. In humans, co-administration of theacrine (125 mg) and caffeine (150 mg), compared to caffeine alone (275 mg) or placebo, resulted in sustained focus and concentration under fatigue-inducing conditions as well as enhanced alertness, attention, and information processing.
Evidence strength: Weak to preliminary for exercise performance in isolation. Research in trained athletes is sparse, and most studies that demonstrated performance-related effects used theacrine as a component of multi-ingredient formulas alongside caffeine.
The anti-inflammatory and analgesic effects of theacrine, a purine alkaloid abundantly present in Camellia kucha, were investigated. Xylene-induced ear edema, acetic acid-induced vascular permeability, and lambda-carrageenan-induced paw edema were used to investigate anti-inflammatory activity, and acetic acid-induced writhing and hot-plate tests were used to determine analgesic effect.
Oral administration of theacrine (8–32 mg/kg) induced dose-related anti-inflammatory and analgesic effects. On the other hand, oral caffeine administration (8–32 mg/kg) did not show an inhibitory effect on inflammation or cause analgesia.
Evidence strength: Preclinical only (animal models). No controlled human trials have been conducted specifically to evaluate theacrine as an analgesic or anti-inflammatory agent.
In studies in mice, theacrine protected against liver damage by reducing the levels of inflammatory cytokines IL-1β, TNF-α, IL-6, and IFN-γ. It also increased the antioxidant capacity of the blood and liver of stressed mice. Theacrine increased the production of the antioxidant enzymes superoxide dismutase, catalase, and glutathione peroxidase, and reduced the activity of xanthine oxidase.
Evidence strength: Preclinical only. Evidence is limited to animal and cell-based studies; no human clinical trials have evaluated theacrine's antioxidant activity as a primary endpoint.
Theacrine is shown to be stimulatory when used in higher doses; however, it can actually have a sedative effect when used in low doses such as the amount consumed through the tea leaves of C. kucha. Theacrine significantly enhanced pentobarbital-induced sleep in mice by shortening wake time and increasing NREMS time, but had no effect on REMS. Theacrine significantly reversed the decrease in sleeping time in mice pretreated with the adenosine A1 receptor antagonist DPCPX.
In the human sleep study described above (2024, Scientific Reports), the authors investigated a low (100 mg) and high (400 mg) dose of theacrine consumed at different times relative to bedtime. They found no significant effect of the low or high theacrine dose on subsequent sleep, although the high dose showed small non-significant effects on sleep efficiency and wake after sleep onset at each timepoint of consumption.
Evidence strength: Preclinical mechanistic evidence for sedative effects at low doses is from animal models. The single human study addressing sleep found no significant sleep disruption even at 400 mg, though the sample was small (22 males) and the study was not designed to assess a hypnotic effect in humans.
Theacrine ameliorates lipid metabolism by activating the SIRT3/AMPK/ACC pathway and downregulating the mRNA and protein levels of fatty acid synthase, fatty acid translocase, and stearoyl-coenzyme A desaturase. Separately, the 8-week human safety trial noted a finding related to cholesterol. Theacrine supplementation did not affect body composition measures, but reduced LDL and total cholesterol. This finding has potential implications for theacrine supplementation as a 'nutraceutical' modality for hypercholesterolemic individuals.
Evidence strength: The mechanistic pathway data are preclinical. The human lipid finding emerged as a secondary observation in a safety trial, not a primary lipid-lowering investigation; it requires dedicated study before conclusions can be drawn.
Theacrine showed antidepressant effects in mice, including shortening the immobility time in the tail suspension test, enhancing the rotatory locomotor activities during the forced swimming test, increasing the mortality induced by yohimbine, and increasing the head-twitching number induced by 5-HTP.
Evidence strength: Preclinical only (animal models). No controlled human clinical trials evaluating antidepressant properties have been published.
The fresh young leaves and shoots of kucha are picked by indigenous populations to prepare an herbal tea for the empirical treatment of common cold. Two extra compounds—chlorogenic acid and theacrine—were detected in Kucha tea compared with Pu'er tea. These compounds were evaluated for their cytotoxicity and inhibitory effects on human influenza virus A/Puerto Rico/8/34 by analyzing viral proteins. It is suggested that theacrine and strictinin are two major ingredients responsible for the anti-influenza activity of Yunnan Kucha tea traditionally used for the treatment of common cold.
Evidence strength: Very preliminary; evidence is from in vitro viral assays, not human clinical trials.
Based on the totality of the peer-reviewed literature reviewed above, the following body systems and health domains have been investigated in connection with theacrine:
The following doses are reported directly from the primary literature and should not be interpreted as recommended clinical doses:
The acute toxicity test in mice showed an LD50 of theacrine of 810.6 mg/kg (769.5–858.0 mg/kg). In animal studies, theacrine has an LD50 of 810 mg/kg, compared to 265 mg/kg for caffeine. The acute toxicity for theacrine ingestion in mice has been reported to be an LD50 of 810.6 mg/kg, which would equate to roughly 4.0 g for an individual weighing 76 kg.
Four-week oral administration of pure theacrine in rats at doses up to 150 mg/kg body weight/day showed that the appearance and behavior, body weights, organ coefficients, and hematological and biochemical parameters of the tested rats were normal compared to the control group. Pathological examination showed no changes induced by drug toxicity, and no delayed toxic reaction was observed after stopping the drug.
A 90-day oral toxicological evaluation showed that the no observed adverse effect level (NOAEL) of theacrine was 180 mg/kg body weight/day, as at this dose there were no toxicologically relevant treatment-related findings in male or female animals.
Oral administration testing in sixty healthy men and women using TeaCrine®, a nature-identical, chemically equivalent bioactive version of theacrine, confirmed that daily supplementation of theacrine up to 300 mg/day for more than 8 weeks was clinically safe, without habituating neuro-energetic effects.
All values for clinical safety markers fell within normal limits and no group Ă— time interactions were noted. No evidence of habituation was noted, as baseline values for energy, focus, concentration, anxiety, motivation to exercise, and POMS remained stable in all groups across the study period.
Theacrine supplementation did not affect body composition measures, but reduced LDL and total cholesterol. Theacrine supplementation did not alter hemodynamic measures or serum measures associated with clinical safety, and lower and higher doses appear to be well-tolerated in humans over an 8-week period.
There was no evidence of a tachyphylactic response that is typical of neuroactive agents such as caffeine and other stimulants. Theacrine, similar to caffeine, exerts psychostimulatory action via modulation of the adenosinergic and dopaminergic pathways. Unlike caffeine, however, theacrine does not appear to be associated with tolerance, nor does it negatively affect the cardiovascular system.
Co-administration of theacrine and caffeine results in a clinically significant pharmacokinetic interaction: increased theacrine exposure. Enhanced oral bioavailability is the most likely mechanism by which caffeine alters theacrine exposure. Further studies examining the contribution of presystemic elimination mechanisms (e.g., efflux transport and/or gut metabolism) are needed to confirm the exact mechanism(s). Hemodynamic parameters were unaltered despite the pharmacokinetic interaction, suggesting that co-administration of caffeine and theacrine is safe at the doses administered.
Caffeine co-administration increased the maximum plasma concentration and area under the curve of theacrine without altering theacrine's half-life. Theacrine had no impact on caffeine or paraxanthine pharmacokinetics.
Theacrine, while it may be a CYP1A2 substrate, is not a clinically significant CYP1A2 inhibitor, based on the finding that it did not affect caffeine clearance in the pharmacokinetic interaction study.
The researchers in the drug–drug interaction study have received research funding from Compound Solutions, Inc., including for this study. These contracts paid for direct and indirect costs, as well as salary. The study was funded by Compound Solutions, Inc., which was consulted in the design of the study. This is a recurring pattern in the theacrine literature — multiple key studies have been funded by or conducted in collaboration with the proprietary ingredient's manufacturer — and this funding relationship should be considered when weighing the totality of the evidence.
One limitation to the 8-week safety study includes the relatively short duration of the supplementation protocol. There is only a limited amount of research on theacrine supplementation in humans, making that study the first of its kind. Long-term human safety data beyond 8 weeks, as well as data in special populations (pregnant women, older adults, individuals with cardiovascular or hepatic conditions), are absent from the published literature.
Health conditions that Teacrine may help support.
Teacrine is the brand name (TeaCrine) for a nature-identical, standardized form of theacrine. Clinical safety and efficacy trials (6+ human RCTs) confirm its energy-promoting, fatigue-reducing effects via adenosine and dopamine receptor modulation, without habituation over 8 weeks of daily use up to 300 mg/day.
Theacrine (marketed as TeaCrine®) is a purine alkaloid from kucha tea (Camellia assamica) structurally analogous to caffeine. It acts as an adenosine receptor antagonist and dopaminergic agonist. A double-blind RCT (n=60) found significantly improved energy, concentration, and focus vs. placebo. Unlike caffeine, it reportedly shows less rapid tolerance development.
Body systems that Teacrine may help support.
Go back